Back to search

Boston University

Differential effects of glycogen synthase kinase 3 inhibitors on migration in glioblastoma cell lines

Abstract

dc:description.abstract

Glioblastoma multiforme (GBM) represents the deadliest brain cancer pathology. Current therapeutic treatment focuses on surgical resection of tumors, followed by adjuvant radiation and/or chemotherapy. The invasive nature of GBM however limits the effectiveness of such therapy. Drug development for GBM has centered on attempts to manage this infiltrative capacity. One avenue of such development focuses on aberrant cellular signaling pathways characteristic of malignancies. This study sought to understand the mechanism by which glycogen synthase kinase 3 (GSK-3) inhibitors differentially regulate GBM migration. Measurement of in vitro cellular migration has traditionally utilized Boyden chamber (transwell) assays and collagen migration assays. Administration of known GSK-3 inhibitors demonstrate a differential effect, whereby migration is inhibited in transwell assays, but maintained in the collagen assay. Cell aggregates from 4 different GBM cell lines were utilized in comparison of GSK-3 inhibitor effects in both the transwell and collagen assays. Contrary to previous findings, GSK-3 inhibitors demonstrated limited effect in reducing migration in the transwell assay, while demonstrating modest effects in the collagen assay. A mechanistic understanding of GSK-3 inhibitor function remains elusive. Previous studies have demonstrated GSK-3 effects on various cytoskeletal proteins, including the WAVE-2 complex, vital for cytoskeletal stability. Administration of GSK-3 inhibitors had previously led to a downregulation of WAVE2 levels. After administration of known GSK-3 inhibitors, this study failed to reproduce previous differences in total WAVE2 protein levels compared to control untreated samples. This evidence indicates a different mode of cytoskeletal regulation must be driving GSK-3 inhibition’s effect on GBM migration. GSK-3 inhibitors represent one promising class of chemotherapeutic agents for treatment of GBM. This study corroborated previous findings about the effect of classical GSK-3 inhibitors (BIO, CHI99021) in reducing GBM migration. Further investigation is necessary to isolate the specific cellular mechanisms responsible for GSK-3’s effects. With rapid development of other therapeutic strategies, GSK-3 inhibitors present one class of drugs available to clinicians for effective therapeutic management of GBM.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2017

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Mahapatra, Shreyas

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/23819

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Mahapatra, Shreyas. Differential effects of glycogen synthase kinase 3 inhibitors on migration in glioblastoma cell lines. masters thesis, Boston University, 2017. https://hdl.handle.net/2144/23819